Iparomlimab/Tuvonralimab

艾帕洛利单抗/托沃瑞利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameIparomlimab/Tuvonralimab
Drug Alias Name艾帕洛利托沃瑞利单抗Alpaloritovorelli齐倍安QL-1706PSB-205 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockersCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursMicrosatellite instability-high cancerMismatch Repair Deficient Cancer +[34] 
Global Approved IndicationsUterine Cervical Neoplasms
Approved Indications in ChinaUterine Cervical Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2024/09/26
Country/TerritoryUnited StatesMainland China
CombinationsYes
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Cancer HospitalPeking Union Medical College HospitalShanxi Province Cancer Hospital +[17] 
Inactive CompaniesQilu Puget Sound Biotherapeutics Corp
Active IndicationsSolid tumoursMicrosatellite instability-high cancerMismatch Repair Deficient Cancer +[33] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A